Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Partners With Korea’s Samsung Bioepis On Multiple Biosimilar Targets

This article was originally published in The Pink Sheet Daily

Executive Summary

Samsung Bioepis will be responsible for development, manufacturing and registration, while Merck will be responsible for commercializing any resulting drugs. Merck says the partnership will complement the firm’s internal biologics portfolio.

You may also be interested in...



Merck Plans Lantus Follow-On This Year, Releases Phase III Data At ADA

Merck released positive Phase III data on its follow-on biologic, insulin glargine, for diabetes at the American Diabetes Association Scientific Sessions, positioning the insulin category for fierce pricing competition.

Merck’s Revised Biosimilar Strategy Poised To Deliver

The big pharma has five biosimilars in Phase III development with its partner Samsung Bioepis, and expects to file them for regulatory approval in 2015 and 2016.

Generic Industry Specialization, Consolidation Driven By Rising Product Complexity

The generic market is moving toward more complex products and formulations, which will separate companies based on capabilities, CEOs said at the Generic Pharmaceutical Association annual meeting.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS075296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel